Peer-reviewed publications

82. Dufresne, Olivier. ESMO Rare Cancers–a brighter future for patients with rare cancers. ESMO Rare Cancers. November 12, 2024.

81. Prasad, Haslam, Olivier. Are Blood-based Cancer Screening Tests Ready for Primetime? American Journal of Medicine. November 8, 2024.

80. Olivier, Haslam, Ochoa, Fernandez, Prasad. Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more. BMJ Oncology. 2 October 2024.

79. Srinivasan, Olivier, Haslam, Prasad. Imatinib remains the best frontline therapy in patients with chronic myeloid leukemia: Critical analysis of the ASC4FIRST trial. Am Journal Hematol. 28 September 2024

78. Schulte, Hwang, Horvai, Olivier. When destiny doesn’t pan out: Implications for the treatment of sarcomas after the agnostic approval of trastuzumab deruxtecan. Cancer. 2024;1‐5.

77. Haslam, Ranganathan, Prasad, Olivier. CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms. Eur J Cancer. June 29, 2024.

76. Olivier, Haslam, Burke, Boutron, Naudet, Ioannidis, Prasad. A novel framework to assess haematology and oncology registration trials: The THEOREMM project. European Journal of Clinical Investigation. June 27, 2024

75. Olivier, Haslam, Prasad. Postrecurrence Treatment in Neoadjuvant or Adjuvant FDA Registration Trials. A Systematic Review. JAMA Oncology. Online 20 June 2024

74. Olivier. Interpreting a randomized trial in oncology: Key points for the clinician. Rev Med Suisse 2024 ; 20 : 954-9

73. Olivier, Haslam, Prasad. Health-Related Quality Of Life In Trials with High Rates of Early Censoring: Caution Advised. Eur J Cancer. March 20, 2024. Online 6 May 2024, 114105

72. Schulte, Mach, Olivier. Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcomas: Looking Forward to What Is Next. Journal of Clinical Oncology. Correspondence. May 03, 2024

71. Ranganathan, Prasad, Olivier. The fate of sotorasib: a regulatory failure potentially harming patients. Lancet Oncology. May 2024.

70. Olivier, Prasad. Neoadjuvant followed by adjuvant pembrolizumab in melanoma: time biases in the data analysis of the SWOG S1801 trial. Translational Oncology. Volume 45, July 2024, 101959.

69. Lesan, Olivier, Prasad. Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials. Eur J Cancer. March 20, 2024.

68. Borgeaud, Parikh, Banna, Kim, Olivier, Le, Addeo. Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer - A Systematic Review. Journal of Thoracic Oncology. Online March 16, 2024.

67. Weiner, Olivier, Addeo. Homologous recombinant repair gene mutations across tumors. Cancer Research, Statistics, and Treatment 7(1):p 131-132, Jan–Mar 2024.

66. Lam, Olivier, Haslam, Tuia, Prasad. Cisplatin Shortage Results In Substitution of More Expensive Treatments: Drug Cost Analysis. Eur J Cancer. 2024. 114019.

65. Olivier, Prasad. Equal censoring but still informative: When the reasons for censoring differ between treatment arms. Eur J Cancer. 2024. :113942.

64. Wu, Benjamin, Prasad, Olivier. Evaluating regulatory consistency for international anti-PD-(L)1 clinical trials. Eur J Cancer. 2024 Apr:201:113925.

63. Olivier, Addeo. Shrinking sample sizes in lung cancer trials: Various explanations, open questions. Eur J Cancer. 2024 Mar:199:113527.

62. Olivier, Prasad. Sotorasib in KRASG12C mutated lung cancer. Lancet. 2024 Jan 13;403(10422):145.

61. Miljković, Tuia, Olivier, Haslam, Prasad. Cancer Drug Price and Novelty in Mechanism of Action. JAMA Netw Open. 2023;6(12):e2347006.

60. Olivier, Addeo. Tumor Treating Fields therapy in metastatic non-small-cell lung cancer. Lancet Oncology. December 2023.

59. Olivier, Hasla, Tuia, Prasad. Eligibility for Human Leukocyte Antigen–Based Therapeutics by Race and Ethnicity. JAMA Netw Open. 2023;6(10):e2338612.

58. Olivier, Haslam, Prasad. Additional considerations before using a ctDNA-guided approach for informing adjuvant chemotherapy in colorectal cancer. BMC Medicine. Published: 08 September 2023.

57. Lam, Olivier, Haslam, Tuia, Prasad. Cost of Drug Wastage From Dose Modification and Discontinuation of Oral Anticancer Drugs. JAMA Oncology. Online 20 July 2023.

56. Olivier, Prasad. Costs per event averted in the neoadjuvant and adjuvant settings of early triple-negative breast cancer. Annals of Oncology. Online 8 July 2023.

55. Olivier, Smith, Haslam, Addeo, Prasad: Quality Of Life In The Adjuvant Setting: A Meta-Analysis of US Food and Drug Administration Approved Anti-Cancer Drugs From 2018 To 2022. Journal of Cancer Policy. Online 2 June 2023, 100426.

54. Olivier, Haslam, Prasad: Post‑progression treatment in cancer randomized trials: a cross‑sectional study of trials leading to FDA approval and published trials between 2018 and 2020. BMC Cancer (2023) 23:448.

53. Olivier, Prasad: PARP inhibitors and overall survival in ovarian cancer, reevaluation advised in all settings. Journal of Cancer Research and Clinical Oncology. Online 10 May 2023.

52. Olivier, Haslam, Prasad: Is Financial Toxicity Captured in Assessments of Quality of Life In Oncology Randomized Clinical Trials? Journal of Cancer Policy. Online 17 April 2023, 100423.

51. Haslam, Olivier, Prasad: The definition of long COVID used in interventional studies. European Journal of Clinical Investigation. e13989.

50. Olivier, Migliorini: Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma: What happened to the evidence? Revue Neurologique. Available online 1 April 2023.

49. Olivier, Haslam, Prasad: Omission of Critical Information From Clinical Trial Reports—What to Do About Uninterpretable Results. JAMA Oncology. February 23, 2023.

48. Olivier, Tsantoulis, Prasad: Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer. European Urology. February 11, 2023.

47. Varatharajan, Olivier, Prasad : Prostate-specific Membrane Antigen Positron Emission Tomography in the Staging of Newly Diagnosed Prostate Cancer: Is More Sensitivity Always Better? European Urology. February 10, 2023

46. Haslam, Olivier, Tuia, Prasad: Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers. BMC Cancer volume 23, Article number: 46 (2023)

45. Haslam, Olivier, Prasad: Design, power, and alpha levels in randomized phase II oncology trials. ESMO Open. Volume 8, Issue 1, February 2023, 100779

44. Powell, Marquart, Olivier, Prasad: The role of surgery in metastatic cancer: the case for a pragmatic tumor-agnostic randomized trial. Future Oncology. Published online: 9 January 2023

43. Olivier, Haslam, Prasad: Sotorasib in KRASG12C mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival? Translational Oncology. Volume 28, February 2023, 101591

42. Powell, Olivier, Prasad: A novel trial methodology to test interventions with very large effect sizes: the case of dostarlimab in mismatch repair-deficient, locally advanced rectal cancer. Trials. 2022 Dec 24;23(1):1044.

41. Krämer, Bochtler, Pauli, Baciarello, Delorme, Hemminki, Mileshkin, Moch, Oien, Olivier et al: Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. December 20, 2022.

40. Haslam, Olivier, Tuia, Prasad: A systematic review of basket and umbrella trials in oncology: the importance of tissue of origin and molecular target. European Journal of Cancer. 2023 Jan;178:227-233.

39. Olivier, Prasad: Molecular testing to deliver personalized chemotherapy recommendations: risking over and undertreatment. BMC Medicine. 2022 20:392

38. Miljković, Tuia, Olivier, Haslam, Prasad: Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020. JAMA Internal Medicine. 2022 Oct 31.

37. Tuia, Olivier, Prasad: Crossover in Adjuvant Trastuzumab Trials: Sparing Toxicity in Patient Care. American Journal of Clinical Oncology. 2022 Oct 1;45(10):438-441.

36. Jenei, Haslam, Olivier, Miljkovíc, Prasad: What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015-2020). BMJ Open. 2022 Oct 7;12(10):e064458.

35. Olivier, Prasad: Neoadjuvant checkpoint inhibition in non-small cell lung cancer: Is earlier unquestionably better than later? Translational Oncology. 2022 Oct;24:101505.

34. Frisone, Sandoval, Friedlaender, Olivier (co-last), Addeo: Trends in incidence and mortality of lung cancer in Switzerland: Possible explanations and open questions. Cancer Epidemiology. 2022 Oct;80:102232.

33. Prasad, Olivier, Chen, Haslam: Estimation of time cost of anti-cancer drugs approved based on comparisons to best supportive care: a cross sectional analysis. Journal of Cancer Policy. 2022 Sep 23;100363.

32. Olivier, Powell, Prasad: Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. European Urology. 2022 Sep 9;S0302-2838(22)02613-6.

31. Olivier, Haslam, Prasad: Dose modification rules and availability of growth factor support: A cross-sectional study of head-to-head cancer trials used for US FDA approval from 2009 to 2021. European Journal of Cancer. 2022 Sep;172:349-356.

30. Olivier, Prasad: Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current Guidelines. Translational Oncology. 2022 Jul 1;23:101475.

29. Olivier, Prasad: FDA precedents in drug approvals: Contradiction in promoting more treatment options. European Journal of Cancer. 2022 May 9;169:123-125.

28. Haslam, Olivier, Powell, Tuia, Prasad: Eventual success rate and predictors of success for oncology drugs tested in phase I trials. International Journal of Cancer. 2022 Jun 18.

27. Olivier, Prasad, Marini. Hard-wired biases in trials: maintenance azacitidine in patients with acute myeloid leukemia and framework for future trials. Blood Advances. 2022 Mar 14;bloodadvances.2021006857.

26. Mousavi, Olivier, Prasad: Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022. JAMA Network Open. 2022 Jun 1;5(6):e2216058.

25. Haslam, Olivier, Thawani, Prasad: Duration of treatment in oncology clinical trials: does the duration change when the same drug moves from the experimental arm to the control arm? ESMO Open. 2022 Apr 22;7(3):100480.

24. Olivier, Prasad: Tebentafusp in first-line melanoma trials: An outperforming outlier. Translational Oncology. 2022 Jun;20:101408.

23. Olivier, Prasad: Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti-PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial. Journal of Clinical Oncology. 2022 May 10;40(14):1596-1597.

22. Olivier, Prasad: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA. Translational Oncology. 2022 Apr;18:101374.

21. Olivier, Gill, Prasad: Reply. The American Journal of Medicine. Volume 136, Issue 3, e48, March 2023

20. Olivier, Gill, Prasad: Multi-cancer screening tests: communicating about risks should be prioritized. The American Journal of Medicine, 2021

19. Olivier, Haslam, Prasad: Reporting of Physicians’ Choice or Investigators’ Choice of Treatment in Oncology Randomized Trials. JAMA Network Open 5(1):e2144770, 2022

18. Olivier, Prasad: Elacestrant in metastatic breast cancer: Is the “standard of care” meeting standard requirements? Translational Oncology 15:101273, 2022

17. Olivier, Prasad: Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm. Translational Oncology 15:101248, 2022

16.  Olivier, Haslam, Prasad: Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action. JAMA Network Open 4:e2138793–e2138793, 2021

15. Lythgoe, Olivier, Prasad: The iceberg plot, improving the visualisation of therapy response in oncology in the era of sequence-directed therapy. European Journal of Cancer 159:56–59, 2021

14. Olivier, Haslam, Prasad: Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials. Journal of Clinical Epidemiology 139:80–86, 2021

13. Olivier, Fernandez, Labidi-Galy, et al: Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm? Cancer Treatment Reviews 97, 2021

12. Thouvenin, Olivier (co-first), Banna, Addeo, Friedlaender. Immune checkpoint inhibitor induced aseptic meningitis and encephalitis: a case-series and narrative review. Therapeutic Advances in Drug Safety 2021.

11. Labidi-Galy, de La Motte Rouge, Derbel, Wolfer, Kalbacher, Olivier, et al. Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers. Gynecol Oncol 2019

10. Banna, Olivier, Rundo, et al. The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy. Front Med 2019

9. Ferraioli, Peñuela, Garuti, Carrozzi, Olivier, et al: Schlafen 11 assessment in high-grade serous ovarian carcinoma phenotypic and histological distribution. Analytical and Quantitative Cytopathology and Histopathology 40:222–230, 2018

8. Labidi-Galy, Olivier, Rodrigues, et al. Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer. Clin Cancer Res 2018

7. Köessler, Olivier, Fertani, Marinari, Dutoit, Dietrich. Ipilimumab-related hypophysitis may precede severe CNS immune attack. Ann Oncol 2016

6. Olivier, Chappuis, Tsantoulis. Bioinformatics: a key role in oncology. Revue Medicale Suisse 2016

5. Olivier, Pop, Chouiter Djebaili, et al. Treating metastatic sarcomas locally: a paradoxe, a rationale, an evidence? Critical Review Oncology Hematology 2015

4. Falk, Moureau-Zabotto, Ouali, Penel, Italiano, Bay, Olivier, et al. Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group. Clin Oncol (R Coll Radiol) 2015

3. Le Cesne, Ray-Coquard, Duffaud, Chevreau, Penel, Bui Nguyen, Piperno-Neumann, Delcambre, Rios, Chaigneau, Le Maignan, Guillemet, Bertucci, Bompas, Linassier, Olivier, et al. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. Eur J Cancer 2015

2. Jardel, Sauerwein, Olivier, et al. Management of choroidal metastases. Cancer Treat Rev 2014

1. Olivier, Gastaud, Maschi, Caujolle, Cupissol, Thariat. Metastasis to unusual sites. Bull Cancer 2014

Other academic works

1. Olivier. Qualitative assessment of the control arm in oncology randomized clinical trials. 2024. https://archive-ouverte.unige.ch/unige:175385